Skip to main content

Advertisement

Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data

Fig. 2

EAIR of AEs year-by-year with secukinumab. Patients included in the analysis: PsO: year 1 (N = 5181), year 2 (N = 3268), year 3 (N = 2246), year 4 (N = 1627), and year 5 (N = 1210); PsA: year 1 (N = 1380), year 2 (N = 1183), year 3 (N = 948), year 4 (N = 587), and year 5 (N = 290); AS: year 1 (N = 794), year 2 (N = 700), year 3 (N = 557), and up to year 4 (N = 332). *Data shown for patients (N = 332) with data beyond the week 156 calendar date (up to 4 years). aRates are for the system organ class which includes multiple associated PTs. bRates are for Candida infections high-level term which includes multiple associated PTs. cRates are for PT (IBD PT data are reported for unspecified IBD). dRates are for the Novartis MedDRA Query term which comprises [1] any MI, any CVA, and [2] all other CV events that are fatal, out of a listing of 2200+ terms. AE adverse event, AS ankylosing spondylitis, CV cardiovascular, CVA CV accident, EAIR exposure-adjusted incidence rate per 100 patient-years, IBD inflammatory bowel disease, MedDRA Medical Dictionary for Regulatory Activities, MACE major adverse cardiovascular event, MI myocardial infarction, N number of patients in the analysis, PsO psoriasis, PsA psoriatic arthritis, PT preferred term, SAE serious AE

Back to article page